Developer docs
API playgroundTry for free, no card

Search company profiles

CALYM

Full company profile

uuid0068dtu

Namestring
CALYM
Legal namestring
Association CALYM
Websiteurl
calym.org
Company typeenum
Private
Founded yearint
2011
Descriptiontext

CALYM is a French non-profit association (loi 1901) operating since 2011 as an academic research consortium dedicated to accelerating R&D on lymphoid neoplasms — including lymphomas, lymphoid leukemias, and now, following a 2026 scope expansion, myelomas. The organization holds the Carnot Institute label granted by the French Ministry of Higher Education, Research and Innovation, and coordinates an ecosystem of 18 laboratories of excellence plus, as of 2026, 20 research entities including the internationally recognized cooperative groups LYSA (lymphoma clinical research), Lysarc (first European operational structure for lymphoma clinical research), and IFM (myeloma research across France, Belgium, and Switzerland). Industrial partnership revenues have grown from €11M to €45M over 15 years at greater than 10% annual rates, with ~80% of revenues coming from major international pharmaceutical groups and a stated 2030 target of €100M.

CALYM operates four interconnected technology platforms that span the full R&D value chain from biomarker discovery through Phase III clinical trials. HEMSYS is a free web application for hematology multidisciplinary tumor board meetings (RCP) deployed in 14+ centers with 40,000+ patients, 78,000+ records, and 100+ disease-specific forms. French Connect is a multi-center liquid biopsy platform for ctDNA-based minimal residual disease monitoring across 10 academic centers in France and Switzerland. The Lymphoma Data Hub (LDH) is a cloud platform aggregating 8+ TB of clinical, omics, and imaging data across 17 data types and supporting 8 active AI-driven projects. CeVi is a national biobanking network of 13 ISO 20387-certified centers providing cryopreserved viable lymphoma cells and a simplified regulatory framework for cohort construction.

CALYM's business model is anchored in collaborative R&D partnerships with pharmaceutical and biotechnology companies, supplemented by French SMEs, academic medical centers, and patient advocacy groups such as ELLyE. Industrial sponsors — including Roche, Bristol-Myers Squibb (4-year ATLAS project), and AstraZeneca (HERmathology initiative) — engage CALYM through direct enterprise sales leveraging the consortium's Carnot credentials and academic network, while AI and blockchain partners (Euranova, Embleema, Microsoft via TA4H) provide technology capabilities. The HEMSYS platform is provided free of charge to hematology departments as a freemium adoption mechanism that feeds data and case volume back into the consortium. Go-to-market combines dedicated R&D partnership teams, scientific conferences (SFH, EHA, ESMO AI), the RedTalks webinar series, the Déchocage patient-focused podcast, and targeted communication partnerships such as the 2025 alliance with Edimark. CALYM is directed by Bertrand Nadel (also an Inserm research director at Centre d'Immunologie de Marseille-Luminy) and coordinated by Pr. G. Cartron at CHU Montpellier.

Short descriptiontext

CALYM is a French non-profit academic consortium accelerating R&D on lymphoid neoplasms through public-private partnerships. It serves pharmaceutical, biotech, and academic medical centers via four interconnected technology platforms covering the full R&D value chain from biomarker discovery to Phase III trials.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lymphoma research consortium, hematology R&D services, clinical research partnerships, biobanking network, liquid biopsy ctDNA
Industry5 codes
PRIMARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Hematology R&D Partnership Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

CALYM generates revenue through collaborative R&D partnerships with pharmaceutical companies, biotechs, and medtech companies. Contractual research revenues have grown from €11M to €45M over 15 years (4x growth), with ~80% from major international pharma groups and targeted support for French SMEs and biotechs. The target is €100M in partnership revenues by 2030.

icc.calym.org
2Academic Partnership Programs
TypeManaged Services
Description

CALYM participates in national programs including France 2030, PEPR (Strategic Programs for Innovation), and the Health Industries Technologies Committee (ITS), generating funding and collaborative research opportunities.

icc.calym.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Free access to hematology departments
ModelFreemiumBilling cadenceOthers
Notes

HEMSYS web application is free exclusively for hematology services to structure multidisciplinary team meetings and contribute to national data consolidation.

icc.calym.org
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1HemSys
Description

Web application for Multidisciplinary Team Meetings (RCP) in hematology, providing structured patient data collection and documentation for clinical decision-making.

icc.calym.org
+3 more records
Core offering1 text field

CALYM is an academic research consortium (Institut Carnot CALYM) that operates four interconnected technology platforms — HemSys, French Connect, Lymphoma Data Hub (LDH), and CeVi — to provide collaborative R&D partnership services in lymphoid neoplasms. It connects pharmaceutical companies, biotechs, medtech firms, and academic medical centers to accelerate research from biomarker discovery through Phase III clinical trials. The consortium is coordinated across 18+ research laboratories and leading cooperative groups (LYSA, Lysarc, IFM) under the Carnot label awarded by the French Ministry of Higher Education, Research and Innovation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 4x revenue growth in 15 years (€11M to €45M) with >10% annual growth rate
+3 more records
Product overview1 text field

CALYM operates as a consortium offering four interconnected technological platforms for lymphoid neoplasm research. HemSys is a dedicated RCP (multidisciplinary tumor board) web application structuring hematology consultations across 14+ centers. French Connect provides liquid biopsy ctDNA analysis for MRD monitoring with standardized NGS panels. The Lymphoma Data Hub (LDH) serves as a cloud-based data platform aggregating clinical, omic, and imaging data for AI-driven research. CeVi offers cryopreserved cell biobanking with certified centers across France. These platforms work together to support the full R&D value chain from biomarker discovery through Phase III clinical trials.

Product and service1 record
1HemSys
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1UNITC
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

UNITC is a national consortium for cell and gene therapies in which CALYM serves as a founding member. Together with UNITC and France BioLead, CALYM organized a national CAR in vivo trajectory development workshop gathering over 100 experts to advance France's position in in-vivo CAR-T cell therapies.

icc.calym.org
2France BioLead
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

France BioLead is a federating network in biotherapies and bioproduction from France 2030, serving as initiator and coordinator of the CAR in vivo national trajectory in collaboration with CALYM/UNITC. The partnership aims to build a complete dossier for French CAR in vivo development.

icc.calym.org
Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2025-11-24
Description

Edimark is a recognized scientific and medical communication specialist in editorial and audiovisual content for healthcare professionals. The partnership aims to strengthen visibility of CALYM network research and innovations nationally.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Independent network of expert professionals and international leader in clinical research on lymphoma and chronic lymphocytic leukemia. LYSA is one of CALYM's foundational cooperative groups driving major advances in lymphoma treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

First European operational structure for clinical research on lymphoma and CLL, operating as a foundational cooperative group within the CALYM consortium.

6IFM (Intergroupe Francophone du Myélome)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cooperative group of expert clinicians and biologists specializing in myeloma across France, Belgium, and Switzerland, conducting fundamental, translational, and clinical research. Five new entities including IFM are joining CALYM in 2026.

icc.calym.org
7Paris-Saclay Cancer Cluster (PSCC)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partnership between Carnot institutes OPALE and CALYM with Paris-Saclay Cancer Cluster to accelerate onco-hematology research and support therapeutic innovation, launched during September Rouge.

icc.calym.org
Strategic tierSupportingTypeTechnology or Integration
Description

Blockchain-based patient consent management for clinical studies and regulatory-compliant evidence generation through HIVE big data platform, used by FDA and CDISC for cell and gene therapy standards.

Strategic tierSupportingTypeTechnology or Integration
Description

AI-powered medical imaging solutions for lymphoma diagnosis, including automated pathological data generation and therapy decision support through advanced artificial intelligence.

10Bristol-Myers Squibb (BMS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ATLAS project: 4-year public-private collaboration building a cellular 'ATLAS' of biological parameters associated with tumor transformation, growth, relapse, and treatment resistance, using CeVi biological samples and LYSA clinical expertise.

icc.calym.org
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

HERmathology initiative partnership supporting the Women in Lymphoma global study on gender equity in hematology leadership, clinical trials access, and mentorship across 34 countries.

12ELLyE (Ensemble Leucémie Lymphomes Espoir)
Strategic tierSupportingTypeGTM or Marketing Partner
Description

Patient association partnership for lymphoma research advocacy, including Dr. Nadel's appearance on Déchocage podcast to discuss follicular lymphoma, patient journey, and innovation sovereignty.

icc.calym.org
Strategic tierSupportingTypeTechnology or Integration
Description

TA4H project: Structured data extraction from multidisciplinary team meetings (RCP) using free-text analysis through Microsoft technology partnerships.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

National research collaboration including RIBB, PEPR, and INSERM partnerships for CAR in vivo national trajectory development and spatial omics research (SpatialOmics project).

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CALYM

Hematology R&D Partnership Servicescalym.org

CALYM is a French non-profit academic consortium accelerating R&D on lymphoid neoplasms through public-private partnerships. It serves pharmaceutical, biotech, and academic medical centers via four interconnected technology platforms covering the full R&D value chain from biomarker discovery to Phase III trials.

What CALYM does

CALYM is a French non-profit association (loi 1901) operating since 2011 as an academic research consortium dedicated to accelerating R&D on lymphoid neoplasms — including lymphomas, lymphoid leukemias, and now, following a 2026 scope expansion, myelomas. The organization holds the Carnot Institute label granted by the French Ministry of Higher Education, Research and Innovation, and coordinates an ecosystem of 18 laboratories of excellence plus, as of 2026, 20 research entities including the internationally recognized cooperative groups LYSA (lymphoma clinical research), Lysarc (first European operational structure for lymphoma clinical research), and IFM (myeloma research across France, Belgium, and Switzerland). Industrial partnership revenues have grown from €11M to €45M over 15 years at greater than 10% annual rates, with ~80% of revenues coming from major international pharmaceutical groups and a stated 2030 target of €100M.

CALYM operates four interconnected technology platforms that span the full R&D value chain from biomarker discovery through Phase III clinical trials. HEMSYS is a free web application for hematology multidisciplinary tumor board meetings (RCP) deployed in 14+ centers with 40,000+ patients, 78,000+ records, and 100+ disease-specific forms. French Connect is a multi-center liquid biopsy platform for ctDNA-based minimal residual disease monitoring across 10 academic centers in France and Switzerland. The Lymphoma Data Hub (LDH) is a cloud platform aggregating 8+ TB of clinical, omics, and imaging data across 17 data types and supporting 8 active AI-driven projects. CeVi is a national biobanking network of 13 ISO 20387-certified centers providing cryopreserved viable lymphoma cells and a simplified regulatory framework for cohort construction.

CALYM's business model is anchored in collaborative R&D partnerships with pharmaceutical and biotechnology companies, supplemented by French SMEs, academic medical centers, and patient advocacy groups such as ELLyE. Industrial sponsors — including Roche, Bristol-Myers Squibb (4-year ATLAS project), and AstraZeneca (HERmathology initiative) — engage CALYM through direct enterprise sales leveraging the consortium's Carnot credentials and academic network, while AI and blockchain partners (Euranova, Embleema, Microsoft via TA4H) provide technology capabilities. The HEMSYS platform is provided free of charge to hematology departments as a freemium adoption mechanism that feeds data and case volume back into the consortium. Go-to-market combines dedicated R&D partnership teams, scientific conferences (SFH, EHA, ESMO AI), the RedTalks webinar series, the Déchocage patient-focused podcast, and targeted communication partnerships such as the 2025 alliance with Edimark. CALYM is directed by Bertrand Nadel (also an Inserm research director at Centre d'Immunologie de Marseille-Luminy) and coordinated by Pr. G. Cartron at CHU Montpellier.

CALYM firmographics

Firmographics
Name
CALYM
Legal name
Association CALYM
Website
https://calym.org
Company type
Private
Founded year
2011
Operating status
Operating
Short description
CALYM is a French non-profit academic consortium accelerating R&D on lymphoid neoplasms through public-private partnerships. It serves pharmaceutical, biotech, and academic medical centers via four interconnected technology platforms covering the full R&D value chain from biomarker discovery to Phase III trials.
Ownership category
akta.pro rank

CALYM industry classification

Industry
Product category
Hematology R&D Partnership Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • Lymphoma research consortium
  • Hematology R&D services
  • Clinical research partnerships
  • Biobanking network
  • Liquid biopsy ctDNA

Where CALYM is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

CALYM business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Contract Research Services: CALYM generates revenue through collaborative R&D partnerships with pharmaceutical companies, biotechs, and medtech companies. Contractual research revenues have grown from €11M to €45M over 15 years (4x growth), with ~80% from major international pharma groups and targeted support for French SMEs and biotechs. The target is €100M in partnership revenues by 2030.
  2. Academic Partnership Programs: CALYM participates in national programs including France 2030, PEPR (Strategic Programs for Innovation), and the Health Industries Technologies Committee (ITS), generating funding and collaborative research opportunities.

Pricing tiers

ModelBillingPrice
FreemiumOthersFree access to hematology departments

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

CALYM product offering

Product offering

Core offering

CALYM is an academic research consortium (Institut Carnot CALYM) that operates four interconnected technology platforms — HemSys, French Connect, Lymphoma Data Hub (LDH), and CeVi — to provide collaborative R&D partnership services in lymphoid neoplasms. It connects pharmaceutical companies, biotechs, medtech firms, and academic medical centers to accelerate research from biomarker discovery through Phase III clinical trials. The consortium is coordinated across 18+ research laboratories and leading cooperative groups (LYSA, Lysarc, IFM) under the Carnot label awarded by the French Ministry of Higher Education, Research and Innovation.

Product overview

CALYM operates as a consortium offering four interconnected technological platforms for lymphoid neoplasm research. HemSys is a dedicated RCP (multidisciplinary tumor board) web application structuring hematology consultations across 14+ centers. French Connect provides liquid biopsy ctDNA analysis for MRD monitoring with standardized NGS panels. The Lymphoma Data Hub (LDH) serves as a cloud-based data platform aggregating clinical, omic, and imaging data for AI-driven research. CeVi offers cryopreserved cell biobanking with certified centers across France. These platforms work together to support the full R&D value chain from biomarker discovery through Phase III clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • HemSys: Web application for Multidisciplinary Team Meetings (RCP) in hematology, providing structured patient data collection and documentation for clinical decision-making.
  • French Connect
  • LDH (Lymphoma Data Hub)
  • CeVi

Products and services

  • HemSys

Quantifiable outcome

  • 4x revenue growth in 15 years (€11M to €45M) with >10% annual growth rate
  • +3 more outcomes

Companies that use CALYM

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

CALYM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

CALYM partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and supporting.

  • UNITCcoreStrategic or Co-development Partner · 2 June 2026UNITC is a national consortium for cell and gene therapies in which CALYM serves as a founding member. Together with UNITC and France BioLead, CALYM organized a national CAR in vivo trajectory development workshop gathering over 100 experts to advance France's position in in-vivo CAR-T cell therapies.
  • France BioLeadcoreStrategic or Co-development Partner · 17 March 2026France BioLead is a federating network in biotherapies and bioproduction from France 2030, serving as initiator and coordinator of the CAR in vivo national trajectory in collaboration with CALYM/UNITC. The partnership aims to build a complete dossier for French CAR in vivo development.
  • EdimarksupportingGTM or Marketing Partner · 24 November 2025Edimark is a recognized scientific and medical communication specialist in editorial and audiovisual content for healthcare professionals. The partnership aims to strengthen visibility of CALYM network research and innovations nationally.
  • LYSAcoreStrategic or Co-development PartnerIndependent network of expert professionals and international leader in clinical research on lymphoma and chronic lymphocytic leukemia. LYSA is one of CALYM's foundational cooperative groups driving major advances in lymphoma treatment.
  • LysarccoreStrategic or Co-development PartnerFirst European operational structure for clinical research on lymphoma and CLL, operating as a foundational cooperative group within the CALYM consortium.
  • IFM (Intergroupe Francophone du Myélome)coreStrategic or Co-development PartnerCooperative group of expert clinicians and biologists specializing in myeloma across France, Belgium, and Switzerland, conducting fundamental, translational, and clinical research. Five new entities including IFM are joining CALYM in 2026.
  • Paris-Saclay Cancer Cluster (PSCC)supportingStrategic or Co-development PartnerPartnership between Carnot institutes OPALE and CALYM with Paris-Saclay Cancer Cluster to accelerate onco-hematology research and support therapeutic innovation, launched during September Rouge.
  • EmbleemasupportingTechnology or IntegrationBlockchain-based patient consent management for clinical studies and regulatory-compliant evidence generation through HIVE big data platform, used by FDA and CDISC for cell and gene therapy standards.
  • EuranovasupportingTechnology or IntegrationAI-powered medical imaging solutions for lymphoma diagnosis, including automated pathological data generation and therapy decision support through advanced artificial intelligence.
  • Bristol-Myers Squibb (BMS)coreStrategic or Co-development PartnerATLAS project: 4-year public-private collaboration building a cellular 'ATLAS' of biological parameters associated with tumor transformation, growth, relapse, and treatment resistance, using CeVi biological samples and LYSA clinical expertise.
  • AstraZenecasupportingStrategic or Co-development PartnerHERmathology initiative partnership supporting the Women in Lymphoma global study on gender equity in hematology leadership, clinical trials access, and mentorship across 34 countries.
  • ELLyE (Ensemble Leucémie Lymphomes Espoir)supportingGTM or Marketing PartnerPatient association partnership for lymphoma research advocacy, including Dr. Nadel's appearance on Déchocage podcast to discuss follicular lymphoma, patient journey, and innovation sovereignty.
  • MicrosoftsupportingTechnology or IntegrationTA4H project: Structured data extraction from multidisciplinary team meetings (RCP) using free-text analysis through Microsoft technology partnerships.
  • INSERMcoreStrategic or Co-development PartnerNational research collaboration including RIBB, PEPR, and INSERM partnerships for CAR in vivo national trajectory development and spatial omics research (SpatialOmics project).

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

CALYM competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CALYM social profiles

Digital presence

CALYM compliance and trust

Trust signal

Compliance1 record

CALYM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CALYM leadership team

Management profile

Number of profiles

Profiles3 records

CALYM funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CALYM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CALYM

What does CALYM do?

CALYM is an academic research consortium (Institut Carnot CALYM) that operates four interconnected technology platforms — HemSys, French Connect, Lymphoma Data Hub (LDH), and CeVi — to provide collaborative R&D partnership services in lymphoid neoplasms. It connects pharmaceutical companies, biotechs, medtech firms, and academic medical centers to accelerate research from biomarker discovery through Phase III clinical trials. The consortium is coordinated across 18+ research laboratories and leading cooperative groups (LYSA, Lysarc, IFM) under the Carnot label awarded by the French Ministry of Higher Education, Research and Innovation.

Is CALYM a public or private company?

CALYM is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was CALYM founded?

CALYM was founded in 2011.

Where is CALYM based?

CALYM is headquartered in Paris, France, in the Europe region.

How does CALYM make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are academic Partnership Programs.

Does CALYM have an API?

No public API is recorded for CALYM.

What industry is CALYM in?

CALYM's product category is Hematology R&D Partnership Services. Its primary akta.pro industry code is HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales